Literature DB >> 16150119

Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas.

C B Knobbe1, A Trampe-Kieslich, G Reifenberger.   

Abstract

Glioblastomas frequently carry genetic alterations resulting in an aberrant activation of the phosphoinositol-3-kinase (Pi3k)/protein kinase B (Akt) signalling pathway, including most notably phosphatase and tensin homolog (PTEN) mutation, epidermal growth factor receptor (EGFR) amplification and rearrangement, as well as carboxyl-terminal modulator protein (CTMP) hypermethylation [Knobbe et al., (2004) Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Institute, 96, 483-486]. Here, we investigated two further Pi3k/Akt pathway genes, namely PIK3CA (3q26.3) and phosphatidylinositol-3-kinase enhancer (PIKE) (CENTG1, 12q14), for genetic alteration and aberrant expression in a series of 97 primary glioblastomas. Single strand conformation polymorphism (SSCP) analysis of PIK3CA revealed somatic mutations in five tumours (5%). Twelve glioblastomas (12%) showed amplification of PIKE with invariable co-amplification of the adjacent CDK4 gene. All tumours with PIKE amplification as well as the vast majority of glioblastomas without amplification demonstrated increased expression of PIKE-A but not PIKE-S/L transcripts as compared with non-neoplastic brain tissue. Taken together, our data support an important role of PIK3CA and PIKE gene aberrations in the molecular pathogenesis of primary glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150119     DOI: 10.1111/j.1365-2990.2005.00660.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  41 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  What we have learnt about PIKE from the knockout mice.

Authors:  Chi Bun Chan; Keqiang Ye
Journal:  Int J Biochem Mol Biol       Date:  2011-06-07

Review 3.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

4.  Brain cancer stem cells display preferential sensitivity to Akt inhibition.

Authors:  Christine E Eyler; Wen-Chi Foo; Katherine M LaFiura; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Stem Cells       Date:  2008-09-18       Impact factor: 6.277

Review 5.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

6.  mTORC2: actin on your memory.

Authors:  Sheena A Josselyn; Paul W Frankland
Journal:  Nat Neurosci       Date:  2013-04       Impact factor: 24.884

7.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 8.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

9.  Automated network analysis identifies core pathways in glioblastoma.

Authors:  Ethan Cerami; Emek Demir; Nikolaus Schultz; Barry S Taylor; Chris Sander
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

10.  Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.

Authors:  John W Barrett; Lindsay R Alston; Fuan Wang; Marianne M Stanford; Philippe-Alexandre Gilbert; Xiujuan Gao; June Jimenez; Danielle Villeneuve; Peter Forsyth; Grant McFadden
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.